Total
0
Shares
Epsilon Healthcare’s (ASX:EPN) Tetra Health launches face-to-face clinic
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Health House International (HHI) has signed a non-exclusive distribution agreement with U.K.-based CBD oils and skincare producer Dragonfly Biosciences
  • Formerly trading as VPCL under the ticker code 'VPC', the company rebranded as Health House International last month after buying out the medicinal cannabis distributor of the same name
  • The deal, which has an initial two-year term, is set to further expand HHI's portfolio of medicinal cannabis products within Australia
  • At this stage, HHI says it cannot fully quantify the impact that the contract will have on the price of its securities
  • The first CBD products are expected to hit Australian pharmacy shelves in mid-2021
  • Health House International shares are down 2.5 per cent, trading at 19.5 cents

Health House International (HHI) has signed a non-exclusive distribution agreement with U.K.-based CBD oils and skincare producer Dragonfly Biosciences.

Formerly trading as VPCL under the ticker code 'VPL', the company rebranded as Health House International last month after buying out the medicinal cannabis distributor of the same name.

The deal, which has an initial two-year term, is set to further expand HHI's portfolio of medicinal cannabis products within Australia.

Health House Chief Operating Officer Australasia Paul Mavor commented on the contract.

"The Dragonfly CBD brand is well known in the U.K. and is already sold over the counter in thousands of pharmacies and health food stores," Paul said.

"We are looking forward to launching Dragonfly’s good manufacturing practice certified, range of medicinal cannabis products to pharmacies throughout Australia."

Dragonfly Biosciences CEO Regan Saveall said the company's CBD range is founded on a "seed-to-shelf" strategy.

"That means that every step from sowing, harvesting, extraction, formulation, to quality testing, ensuring every product contains the advertised amount of CBD oil, is totally transparent," Regan commented.

"Our production process mirrors very strict and safe pharmaceutical processes and why we were the first CBD brand to be stocked by the largest U.K. pharmacy and health retailer, Boots."

"We are delighted with our expansion into Australia and new distribution partnership with Health House International."

At this stage, HHI says it cannot fully quantify the impact that the contract will have on the price of its securities.

The first CBD products are expected to hit Australian pharmacy shelves in mid-2021.

Health House International shares are down 2.5 per cent this afternoon, trading at 19.5 cents at 12:37 pm AEST.

HHI by the numbers
More From The Market Herald
Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.